Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.

Stéphanie DecaryPierre-François BerneCéline NicolazziAnne-Marie LefebvreTarik DabdoubiBéatrice CameronPierrick RivalCatherine DevaudCatherine PradesHervé BouchardAlhassan CasséChristophe HenryCéline AmaraClaire BrillacPaul FerrariLaetitia MaçonEric LacosteCecile CombeauEric BeysSouad NaimiCarlos García-EcheverríaJean-François MayauxVéronique Blanc

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

On the basis of these preclinical data, the ADC SAR408701 is a promising candidate for development as a potential treatment for patients with CEACAM5-positive tumors.

Keyphrases

magnetic resonance imaging
stem cells
cell therapy
machine learning
electronic health record
risk assessment
mesenchymal stem cells
drug delivery
big data
cancer therapy
computed tomography
deep learning
human health